Halaven is prescribed to treat breast cancer in people who have late-stage cancer that has not responded adequately to other chemotherapy treatments. It is administered intravenously (by IV) over a short period of time. It works by preventing cell division and killing the cancer cells. Potential side effects include hair loss, fatigue, and nerve problems.
What Is Halaven?
Halaven™ (eribulin mesylate) is a chemotherapy medication approved for the treatment of breast cancer. It is licensed to treat late-stage cancer that has not responded to certain other chemotherapy regimens.
Halaven is part of a group of medications called microtubule inhibitors. It works by preventing cell division and, eventually, causing the cell to die.
While Halaven can kill both healthy and cancerous cells, it has a greater effect on cells that are multiplying rapidly. Generally, cancer cells multiply more rapidly than healthy cells and are, therefore, more affected by Halaven.
Effects of Halaven
One study looked at using Halaven to treat metastatic breast cancer (breast cancer that has spread to other parts of the body) in people who had been unsuccessfully treated with certain other types of chemotherapy. People were given either Halaven or a different breast cancer treatment. Those who were given Halaven lived an average of 13.1 months, while those who received other types of treatments lived only 10.6 months, on average.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Halaven [package insert]. Woodcliff Lake, NJ: Eisai, Inc.;2010 November.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed January 6, 2011.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click